Effect of Time Since Death on Multipathogen Molecular Test Results of Postmortem Specimens Collected Using Minimally Invasive Tissue Sampling Techniques.

MITS minimally invasive tissue sampling molecular diagnosis pediatric respiratory death postmortem interval

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
15 12 2021
Historique:
entrez: 15 12 2021
pubmed: 16 12 2021
medline: 16 3 2022
Statut: ppublish

Résumé

We used postmortem minimally invasive tissue sampling (MITS) to assess the effect of time since death on molecular detection of pathogens among respiratory illness-associated deaths. Samples were collected from 20 deceased children (aged 1-59 months) hospitalized with respiratory illness from May 2018 through February 2019. Serial lung and/or liver and blood samples were collected using MITS starting soon after death and every 6 hours thereafter for up to 72 hours. Bodies were stored in the mortuary refrigerator for the duration of the study. All specimens were analyzed using customized multipathogen TaqMan® array cards (TACs). We identified a median of 3 pathogens in each child's lung tissue (range, 1-8; n = 20), 3 pathogens in each child's liver tissue (range, 1-4; n = 5), and 2 pathogens in each child's blood specimen (range, 0-4; n = 5). Pathogens were not consistently detected across all collection time points; there was no association between postmortem interval and the number of pathogens detected (P = .43) and no change in TAC cycle threshold value over time for pathogens detected in lung tissue. Human ribonucleoprotein values indicated that specimens collected were suitable for testing throughout the study period. Results suggest that lung, liver, and blood specimens can be collected using MITS procedures up to 4 days after death in adequately preserved bodies. However, inconsistent pathogen detection in samples needs careful consideration before drawing definitive conclusions on the etiologic causes of death.

Sections du résumé

BACKGROUND
We used postmortem minimally invasive tissue sampling (MITS) to assess the effect of time since death on molecular detection of pathogens among respiratory illness-associated deaths.
METHODS
Samples were collected from 20 deceased children (aged 1-59 months) hospitalized with respiratory illness from May 2018 through February 2019. Serial lung and/or liver and blood samples were collected using MITS starting soon after death and every 6 hours thereafter for up to 72 hours. Bodies were stored in the mortuary refrigerator for the duration of the study. All specimens were analyzed using customized multipathogen TaqMan® array cards (TACs).
RESULTS
We identified a median of 3 pathogens in each child's lung tissue (range, 1-8; n = 20), 3 pathogens in each child's liver tissue (range, 1-4; n = 5), and 2 pathogens in each child's blood specimen (range, 0-4; n = 5). Pathogens were not consistently detected across all collection time points; there was no association between postmortem interval and the number of pathogens detected (P = .43) and no change in TAC cycle threshold value over time for pathogens detected in lung tissue. Human ribonucleoprotein values indicated that specimens collected were suitable for testing throughout the study period.
CONCLUSIONS
Results suggest that lung, liver, and blood specimens can be collected using MITS procedures up to 4 days after death in adequately preserved bodies. However, inconsistent pathogen detection in samples needs careful consideration before drawing definitive conclusions on the etiologic causes of death.

Identifiants

pubmed: 34910183
pii: 6460385
doi: 10.1093/cid/ciab810
pmc: PMC8672767
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S360-S367

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : OPP1168515

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Sci Rep. 2018 Oct 31;8(1):16112
pubmed: 30382145
J Anal Toxicol. 2018 Jul 1;42(6):365-374
pubmed: 29579266
PLoS Med. 2016 Nov 22;13(11):e1002173
pubmed: 27875535
PLoS Med. 2016 Nov 22;13(11):e1002172
pubmed: 27875532
J Trop Med. 2009;2009:718984
pubmed: 20339563
Afr J Med Med Sci. 2007 Sep;36(3):267-72
pubmed: 18390067
BMC Infect Dis. 2017 Aug 25;17(1):591
pubmed: 28841843
Lancet. 2015 Nov 28;386(10009):2141
pubmed: 26638959
Am J Clin Pathol. 2019 Jun 5;152(1):36-49
pubmed: 31006817
Eur J Clin Microbiol Infect Dis. 2015 May;34(5):1045-57
pubmed: 25680317
Leg Med (Tokyo). 2015 Jan;17(1):65-9
pubmed: 25287273
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
Pediatr Dev Pathol. 2012 Jan-Feb;15(1):1-4
pubmed: 21991941
Lancet. 2019 Aug 31;394(10200):757-779
pubmed: 31257127
N Engl J Med. 2008 Feb 28;358(9):873-5
pubmed: 18305264
PLoS One. 2017 Aug 2;12(8):e0181837
pubmed: 28767714
PLoS One. 2015 Jun 30;10(6):e0132057
pubmed: 26126191
Clin Microbiol Infect. 2019 May;25(5):570-579
pubmed: 30145399
Ann Glob Health. 2019 Jul 03;85(1):
pubmed: 31276331
J Clin Pathol. 2006 Jan;59(1):1-9
pubmed: 16394274
J Family Med Prim Care. 2017 Apr-Jun;6(2):191-195
pubmed: 29302514
Arch Dis Child. 2001 Jun;84(6):463-7
pubmed: 11369557
Ulster Med J. 2000 Nov;69(2):83-9
pubmed: 11196736
J Acquir Immune Defic Syndr. 2019 May 1;81(1):18-23
pubmed: 30964803
Lancet Glob Health. 2020 Jul;8(7):e909-e919
pubmed: 32562647
Clin Infect Dis. 2019 Oct 9;69(Suppl 4):S361-S373
pubmed: 31598659
J Clin Microbiol. 2011 Jun;49(6):2175-82
pubmed: 21471348

Auteurs

Jeanette Dawa (J)

Washington State University, Global Health Programs (Kenya Office), Nairobi, Kenya.
College of Health Sciences, University of Nairobi, Nairobi, Kenya.

Edwin Walong (E)

College of Health Sciences, University of Nairobi, Nairobi, Kenya.

Clayton Onyango (C)

Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.

John Mathaiya (J)

Department of Pathology, Thika Level 5 Hospital, Kiambu County, Kenya.

Peter Muturi (P)

Washington State University, Global Health Programs (Kenya Office), Nairobi, Kenya.

Milka Bunei (M)

Washington State University, Global Health Programs (Kenya Office), Nairobi, Kenya.

Washington Ochieng (W)

College of Health Sciences, University of Nairobi, Nairobi, Kenya.

Walter Barake (W)

College of Health Sciences, University of Nairobi, Nairobi, Kenya.

Josilene N Seixas (JN)

Infectious Diseases Pathology Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Lillian Mayieka (L)

Centre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.

Melvin Ochieng (M)

Centre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.

Victor Omballa (V)

Centre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.

Shirley Lidechi (S)

Centre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.

Elizabeth Hunsperger (E)

Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.

Nancy A Otieno (NA)

Centre for Global Health Research, Kenya Medical Research Institute, Nairobi, Kenya.

Jana M Ritter (JM)

Infectious Diseases Pathology Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Marc-Alain Widdowson (MA)

Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.
Institute of Tropical Medicine, Antwerp, Belgium.

Maureen H Diaz (MH)

Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Jonas M Winchell (JM)

Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Roosecelis B Martines (RB)

Infectious Diseases Pathology Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sherif R Zaki (SR)

Infectious Diseases Pathology Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Sandra S Chaves (SS)

Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH